Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Sarepta Therapeutics, Inc. (SRPT : NSDQ)

• Company Description    Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a rare genetic disorder affecting children. The company received accelerated approval for Exondys 51, Amondys 45 (casimersen) and Vyondys 53 (golodirsen). Exondys 51 is Sarepta's first PMO-based technology to be granted accelerated approval by the FDA. The company is conducting a confirmatory study on the clinical benefits of these drugs for gaining continued approval. The rest of its exon-skipping DMD pipeline includes a PPMO-based, exon 51 skipping candidate, SRP-5051. Sarepta is also developing gene therapies for treating DMD, Limb-girdle muscular dystrophy and central nervous system disorders including Mucopolysaccharidosis type IIIA and Pompe Disease. Number of Employees: 840

• Price / Volume Information    Yesterday's Closing Price: $71.13 Daily Weekly Monthly 20 Day Moving Average: 806,639 shares Shares Outstanding: 87.50 (millions) Market Capitalization: $6,223.94 (millions) Beta: 1.29 52 Week High: $101.24 52 Week Low: $61.28 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.90% 1.94% 12 Week -6.44% 5.14% Year To Date -21.01% -3.50%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 215 FIRST STREET SUITE 415 - CAMBRIDGE,MA 02142 USA ph: 617-274-4000 fax: 425-354-5038 iestepan@sarepta.com http://www.sarepta.com

• General Corporate Information    Officers Douglas S. Ingram - Chief Executive Officer and President M. Kathleen Behrens - Chairman Ian M. Estepan - Executive Vice President; Chief Financial Officer Richard Barry - Director Stephen L. Mayo - Director Peer Information Sarepta Therapeutics, Inc. (CORR.) Sarepta Therapeutics, Inc. (RSPI) Sarepta Therapeutics, Inc. (CGXP) Sarepta Therapeutics, Inc. (BGEN) Sarepta Therapeutics, Inc. (GTBP) Sarepta Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 803607100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/03/22 Share - Related Items Shares Outstanding: 87.50 Most Recent Split Date: 7.00 (0.17:1) Beta: 1.29 Market Capitalization: $6,223.94 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.12 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.53 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/03/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 7.26 Price/Cash Flow: - Price / Sales: 8.13 EPS Growth vs. Year Ago Period: 42.86% vs. Previous Quarter: 15.49% Sales Growth vs. Year Ago Period: 43.49% vs. Previous Quarter: 4.65% ROE 03/31/22 - -52.06 12/31/21 - -69.28 09/30/21 - -86.35 ROA 03/31/22 - -12.27 12/31/21 - -14.78 09/30/21 - -17.41 Current Ratio 03/31/22 - 5.56 12/31/21 - 5.75 09/30/21 - 5.85 Quick Ratio 03/31/22 - 5.13 12/31/21 - 5.34 09/30/21 - 5.08 Operating Margin 03/31/22 - -46.56 12/31/21 - -59.67 09/30/21 - -75.30 Net Margin 03/31/22 - -46.56 12/31/21 - -59.67 09/30/21 - -75.30 Pre-Tax Margin 03/31/22 - -46.45 12/31/21 - -59.69 09/30/21 - -75.21 Book Value 03/31/22 - 9.79 12/31/21 - 10.66 09/30/21 - 5.39 Inventory Turnover 03/31/22 - 0.45 12/31/21 - 0.39 09/30/21 - 0.34 Debt-to-Equity 03/31/22 - 1.28 12/31/21 - 1.18 09/30/21 - 2.33 Debt-to-Capital 03/31/22 - 56.19 12/31/21 - 54.17 09/30/21 - 69.99

Powered by Zacks Investment Research ©